Essential Oils for Psoriasis: Human Evidence and Its Limits

HealthWatchlist verdict: Essential oils are not established replacements for psoriasis treatment. A few human formulation studies exist, but their ingredients and comparison groups matter, and newer mouse experiments do not demonstrate human benefit.

Understanding the condition

Psoriasis is an inflammatory skin condition that can cause persistent scaly patches and nail changes. It is not a sign of poor hygiene or something that can simply be disinfected away. Some people also develop joint symptoms.

Skin comfort, plaque severity, quality of life and control of joint disease are separate outcomes. A product that makes skin feel less dry has not necessarily changed the disease process.

The evidence in context

Preparation	Evidence to consider	What remains uncertain
Kunzea oil added to an active topical base	A small randomised trial found no significant added benefit.	It does not support the oil as an effective additional treatment.
Chamomile-pumpkin oleogel	A small study reported improvement in treated plaques.	It used a traditional chamomile extract in oil, not bottled chamomile essential oil alone.
Frankincense-containing herbal cream	A combination study reported benefits.	Several ingredients prevent attribution to frankincense alone.
Tea tree, patchouli or Artemisia delivery systems	Recent experiments include mouse models.	Human effectiveness and safety are not established by those experiments.

An important negative trial

The kunzea-oil trial included 30 people and compared formulations with and without the oil for eight weeks. Both groups received coal-tar solution and salicylic acid in the treatment base. Both improved, without a statistically significant difference between them.

Reporting only that participants improved would miss the main finding: adding kunzea oil did not demonstrate extra benefit over that active base. A control group is what allows an improvement to be interpreted.

Chamomile and frankincense formulations

The chamomile-pumpkin study compared matched plaques within 40 participants over four weeks, with 37 completing the study. The preparation performed better on plaque measures. However, its chamomile component was made from a water extract processed into sesame oil. That is not the same substance as steam-distilled chamomile essential oil.

A frankincense-containing cream trial is also relevant, but the formulation combined frankincense material with pumpkin oil and liquorice extract. The 2024 scoping review describes its positive findings and the limitations of the broader evidence. A combination result cannot tell us which component produced the effect.

These studies should neither be omitted nor turned into endorsements for unrelated bottles. Product identity is part of the evidence, not a minor detail that can be dropped from a summary.

What newer research adds

Artemisia nanoformulations were tested in mice with experimentally induced psoriasis-like skin changes. A tea-tree-releasing experimental dressing and a patchouli microemulsion gel also have preclinical findings. Their delivery materials are part of the intervention.

Reduced inflammation in a mouse model is useful for development, but it does not establish symptom control in people or tell a reader how to make a safe substitute. The word “psoriasis” in a paper title is not enough to make it a human treatment trial.

A systematic review of complementary psoriasis approaches covers several unrelated interventions, including non-oil preparations. Its results cannot be assigned wholesale to essential oils.

Care and safety

NHS guidance describes moisturisers, prescribed topical treatments and specialist options according to severity. Persistent symptoms or troublesome adverse effects are reasons to review treatment with a clinician. Replacing a working treatment with an oil may leave inflammation uncontrolled.

Fragranced essential oils can themselves cause dermatitis. A new itchy rash after adding a product may reflect irritation or allergy. Avoid applying concentrated oils to cracked or inflamed skin, and do not combine products with prescribed light treatment without checking with the treating team.

New recurring joint pain, swelling or stiffness deserves medical assessment. Rapidly worsening widespread skin changes, pus-filled lesions or feeling acutely unwell require urgent care. These are not situations in which to test another topical blend.

Overall conclusion

The strongest reason for caution is the gap between the studied products and the claims made for ordinary essential oils. The negative kunzea comparison and the mixed formulations deserve as much attention as encouraging laboratory results.

For now, the evidence supports further product-specific research. It does not establish a reliable essential-oil treatment for psoriasis or its joint complications.

How this review was researched

Research checked on 12 September 2026. We searched PubMed using the oil or preparation name and the condition, checked relevant reviews and their cited trials, and consulted the official guidance linked below. This is an editorial review, not an exhaustive systematic review. Laboratory findings, combination products and uncontrolled reports are distinguished from controlled evidence for the exact claim.

Seven more psoriasis claims: clinical results and experimental products

These comparisons expand the earlier overview with individual study findings. They distinguish supervised phototherapy, experimental formulations and symptom relief from evidence that an ordinary essential oil controls psoriasis.

Bergamot and psoriasis

A randomised study of 193 people compared broadband UVB alone with UVB plus bergamot oil. The combination required fewer procedures and a lower cumulative UVB dose. However, final psoriasis severity and the duration of remission did not differ significantly. This is a potentially useful treatment-efficiency finding, not proof of better lasting disease control.

The indexed abstract does not provide enough detail to reproduce the formulation, assess all adverse events or judge how the result transfers to current phototherapy practice. It did not test bergamot alone. A clinic-controlled photosensitising regimen cannot be recreated by putting oil on plaques before sun exposure.

Two clinical cases describe blistering phototoxic reactions after bergamot aromatherapy exposure followed by ultraviolet light. The oil’s ability to increase a light response is also a hazard. Ask the phototherapy team about every product used on treated skin.

Related: Bergamot profile.

Clary sage and psoriasis

No controlled human psoriasis treatment trial of Salvia sclarea oil was located in this targeted search. A 2025 experiment reported improved wound contraction, epithelialisation and inflammatory markers after clary sage oil treatment in rats with excision wounds.

That result concerns an open-wound model. Psoriasis involves abnormal skin-cell turnover and immune signalling, so faster closure of a rat wound does not demonstrate plaque clearance, reduced relapse or improvement in psoriatic arthritis. The experiment also does not establish a safe concentration for repeated use on inflamed human skin.

Claims about sclareol or other isolated constituents require another distinction: a purified molecule, a defined experimental formulation and a retail essential oil are different interventions. Clary sage should not replace prescribed psoriasis treatment on the basis of wound-healing or general anti-inflammatory claims.

Related: Clary sage profile.

Geranium and psoriasis

Rose geranium oil reduced experimentally induced swelling in mice, including a croton-oil ear-inflammation model. This was an acute inflammatory challenge, not a human psoriasis trial.

Geranium also appeared in a study of pre-inflamed human skin fibroblasts. Reduced cell proliferation in culture does not establish selective control of psoriatic keratinocytes, the surface cells central to plaques. Neither study measured human plaque severity, relapse or quality of life.

The targeted search did not locate a controlled trial establishing geranium oil as a psoriasis treatment. Its laboratory activity supports a research question; it cannot tell us whether benefit would outweigh irritation or allergy in repeated real-world use. Products labelled geranium can also refer to different plants, so a finding for a different Geranium extract should not be assigned to Pelargonium graveolens oil.

Related: Geranium profile.

Myrrh and psoriasis

A 2025 primary study used a water extract of myrrh in cytokine-stimulated HaCaT keratinocytes. It reduced a proliferation marker and several inflammatory signals. Not all measures improved: the reported TNF-alpha reduction was not significant, and the highest tested concentration was toxic to the cells.

This is a psoriasis-like cell model, not a treatment trial in people. A water extract of the resin is also chemically different from distilled myrrh essential oil. The results do not demonstrate plaque clearance or a safe home preparation.

A separate mast-cell experiment found reduced itch-related mediator release with myrrh. It did not measure itching in patients. A published contact-allergy report involving topical myrrh is a reminder that a traditional healing use does not guarantee tolerance. Only the bibliographic record of that case was available for this appraisal, so it cannot supply a reaction rate.

Related: Myrrh profile.

Patchouli and psoriasis

A 2026 study developed a patchouli-oil microemulsion incorporated into a gel. In mice with imiquimod-induced psoriasis-like inflammation, the formulation improved lesion scores and reduced skin thickening. Laboratory work also assessed stability and retention of components in skin.

The gel’s delivery system is part of the intervention. It is not equivalent to putting diluted patchouli oil on a plaque, and the reported mouse score should not be mistaken for improvement in a human trial. No controlled human psoriasis trial of this preparation was located.

An earlier patchouli gel study used a mouse atopic-dermatitis model; that adds preclinical information about a different condition. Neither experiment establishes long-term human safety. A clinical contact-dermatitis report involving a patchouli product was also located. Its bibliographic record identifies a safety signal, not its frequency or the safety of every formulation.

Related: Patchouli profile.

Peppermint and psoriasis

A 2022 study of isolated L-menthol found effects on a signalling pathway in keratinocytes and improvement in psoriasis-like inflammation in mice and reconstructed skin. Human biopsy material helped investigate the mechanism, but patients were not treated with peppermint oil in a clinical efficacy trial.

The often-cited 50-person peppermint itch study concerned itching associated with kidney disease, liver disease or diabetes. It explicitly excluded psoriasis and contact dermatitis. Although itch scores improved over two weeks, four users reported burning in skin folds. This cannot establish either plaque control or safety on psoriatic skin.

A large referral-clinic patch-test analysis recorded peppermint allergy in 161 of 28,128 tested patients. That selected population cannot estimate the risk for all consumers. Cooling sensation, symptomatic itch relief and control of an inflammatory disease are separate claims; the evidence does not justify replacing psoriasis medicines with peppermint.

Related: Peppermint profile.

Tea tree and psoriasis

The paper titled “Tea tree oil as a novel antipsoriasis weapon” proposed a molecular rationale; it was not a clinical trial. Its title should not be treated as evidence that patients improved.

A curcumin and tea-tree-oil emulgel study and a 2026 oil-releasing collagen/mycelium dressing study reported preclinical effects. The former combined active ingredients, and the latter used a specially engineered patch in a mouse model. Neither establishes the efficacy of bottled oil in human psoriasis.

There is genuine human evidence for another scalp problem: a 126-person dandruff trial found greater improvement with a tea tree shampoo than placebo. Dandruff is not scalp psoriasis, so the result cannot settle a psoriasis claim.

Tea tree can also cause allergy. A case report describes spreading dermatitis after a tea tree product was applied to a wart. An unexplained worsening rash may be a product reaction rather than a reason to increase its strength.

Related: Tea tree profile.

Care in context

Continue clinician-guided treatment. NHS psoriasis guidance describes moisturisers, prescribed topical treatments and specialist options. Recurrent joint pain, stiffness or swelling needs assessment. Rapid widespread redness with pus-filled lesions or acute illness needs urgent medical care. Do not add a photosensitising oil to a light-treatment regimen without the treating team.

Search limitations: Targeted Europe PMC and web searches combined common and botanical plant names with the relevant skin condition, clinical trial, dermatitis, rash and wrinkle terms, with narrower follow-up searches and citation checks, completed 16 September 2026. This is an editorial review, not a systematic review or a complete unpublished-trial search. Indexed abstracts were used where full texts were unavailable; bibliographic-only allergy reports are identified in the text. Failure to locate a trial does not prove that none exists. Full texts were checked for the L-menthol, curcumin/tea tree emulgel and peppermint chronic-itch studies; the publisher report was checked for myrrh water extract. The bergamot UVB appraisal relies on its indexed abstract. The holy-basil registry was checked separately and has no results posted.

References for these comparisons

References

Editor: John Hamlen. This article has not been independently reviewed by a clinician. See our editorial policy, evidence method and corrections policy.

Read favourable turmeric trials alongside the limitations

Evidence update: 13 September 2026.

A small scalp-psoriasis tonic trial reported benefit, while an earlier oral-curcumin pilot had a low response rate. These different formulations cannot be pooled informally into a claim that essential oil works. A 2022 review included seven clinical randomised trials and 19 preclinical studies, not 26 human trials.

Include the negative coconut phototherapy result

Evidence update: 14 September 2026.

A controlled half-body study found no faster psoriasis clearance from coconut oil applied before PUVA or narrow-band UVB. A dry-skin trial supports moisturising effects, but cannot establish psoriasis control. Ask the phototherapy team which products to use before treatment rather than adding oils independently.

Related evidence review: Chamomile Oil for Psoriasis: The Blend Trial and Its Limits.

Essential Oils for Psoriasis: What Human Studies Do and Do Not Show